<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29801515</article-id><article-id pub-id-type="pmc">5970474</article-id><article-id pub-id-type="publisher-id">2659</article-id><article-id pub-id-type="doi">10.1186/s13063-018-2659-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rapp</surname><given-names>Marion</given-names></name><address><phone>+49 (0) 211 / 81-07458</phone><email>marion.rapp@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Grauer</surname><given-names>Oliver M.</given-names></name><address><email>oliver.grauer@ukmuenster.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kamp</surname><given-names>Marcel</given-names></name><address><email>Marcelalexander.kamp@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sevens</surname><given-names>Natalie</given-names></name><address><email>natalie.sevens@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zotz</surname><given-names>Nikola</given-names></name><address><email>nikola.zotz@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sabel</surname><given-names>Michael</given-names></name><address><email>sabel@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sorg</surname><given-names>R&#x000fc;diger V.</given-names></name><address><email>ruediger.sorg@med.uni-duesseldorf.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8922 7789</institution-id><institution-id institution-id-type="GRID">grid.14778.3d</institution-id><institution>Department of Neurosurgery, </institution><institution>Heinrich Heine University Hospital, </institution></institution-wrap>Moorenstr. 5, 40225 D&#x000fc;sseldorf, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0551 4246</institution-id><institution-id institution-id-type="GRID">grid.16149.3b</institution-id><institution>Department of Neurology, </institution><institution>University Hospital M&#x000fc;nster, </institution></institution-wrap>Albert-Schweitzer-Campus 1, 48149 M&#x000fc;nster, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8922 7789</institution-id><institution-id institution-id-type="GRID">grid.14778.3d</institution-id><institution>Coordination Center for Clinical Trials, </institution><institution>Heinrich Heine University Hospital, </institution></institution-wrap>Moorenstr. 5, 40225 D&#x000fc;sseldorf, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8922 7789</institution-id><institution-id institution-id-type="GRID">grid.14778.3d</institution-id><institution>Institute for Transplantation Diagnostics and Cell Therapeutics, </institution><institution>Heinrich Heine University Hospital, </institution></institution-wrap>Moorenstr. 5, 40225 D&#x000fc;sseldorf, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8922 7789</institution-id><institution-id institution-id-type="GRID">grid.14778.3d</institution-id><institution>Department of Neurosurgery, </institution><institution>Heinrich Heine University Hospital D&#x000fc;sseldorf, </institution></institution-wrap>Moorenstr. 5, 40225 D&#x000fc;sseldorf, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>293</elocation-id><history><date date-type="received"><day>18</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Despite the combination of surgical resection, radio- and chemotherapy, median survival of glioblastoma multiforme (GBM) patients only slightly increased in the last years. Disease recurrence is definite with no effective therapy existing after tumor removal. Dendritic cell (DC) vaccination is a promising active immunotherapeutic approach. There is clear evidence that it is feasible, results in immunological anti-tumoral responses, and appears to be beneficial for survival and quality of life of GBM patients. Moreover, combining it with the standard therapy of GBM may allow exploiting synergies between the treatment modalities. In this randomized controlled trial, we seek to confirm these promising initial results.</p></sec><sec><title>Methods</title><p id="Par2">One hundred and thirty-six newly diagnosed, isocitrate dehydrogenase wildtype GBM patients will be randomly allocated (1:1 ratio, stratified by O6-methylguanine-DNA-methyltransferase promotor methylation status) after near-complete resection in a multicenter, prospective phase II trial into two groups: (1) patients receiving the current therapeutic &#x0201c;gold standard&#x0201d; of radio/temozolomide chemotherapy and (2) patients receiving DC vaccination as an add-on to the standard therapy. A recruitment period of 30&#x000a0;months is anticipated; follow-up will be 2 years. The primary objective of the study is to compare overall survival (OS) between the two groups. Secondary objectives are comparing progression-free survival (PFS) and 6-, 12- and 24-month OS and PFS rates, the safety profile, overall and neurological performance and quality of life.</p></sec><sec><title>Discussion</title><p id="Par3">Until now, close to 500 GBM patients have been treated with DC vaccination in clinical trials or on a compassionate-use basis. Results have been encouraging, but cannot provide robust evidence of clinical efficacy because studies have been non-controlled or patient numbers have been low. Therefore, a prospective, randomized phase II trial with a sufficiently large number of patients is now mandatory for clear evidence regarding the impact of DC vaccination on PFS and OS in GBM.</p></sec><sec><title>Trial registration</title><p id="Par4">Protocol code: GlioVax, date of registration: 17. February 2017.</p><p id="Par5">Trial identifier: EudraCT-Number 2017&#x02013;000304-14.</p><p id="Par6">German Registry for Clinical Studies, ID: <ext-link ext-link-type="uri" xlink:href="https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&#x00026;TRIAL_ID=DRKS00013248">DRKS00013248</ext-link> (approved primary register in the WHO network) and at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>, ID: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03395587?term=gliovax&#x00026;cond=glioblastoma&#x00026;rank=1">NCT03395587</ext-link>. Registered on 11 March 2017.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s13063-018-2659-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Glioblastoma</kwd><kwd>Dendritic cells</kwd><kwd>Immunotherapy</kwd><kwd>Vaccination</kwd><kwd>Radiochemotherapy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id><institution>Bundesministerium f&#x000fc;r Bildung und Forschung</institution></institution-wrap></funding-source><award-id>01KG1424</award-id><principal-award-recipient><name><surname>Sabel</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par37">Glioblastoma multiforme (GBM) is the most frequent and aggressive malignant primary brain tumor. The yearly incidence is 3&#x02013;4 per 100,000 adults [<xref ref-type="bibr" rid="CR1">1</xref>]. The established therapeutic standard in the first-line therapy for GBM combines maximal safe resection, fractionated radiotherapy with concomitant alkylating temozolomide (TMZ) chemotherapy followed by adjuvant TMZ. This multimodal approach has improved the survival of patients significantly. Nevertheless, the prognosis of newly diagnosed GBM patients is still poor. Median overall survival (OS) is only 14.6&#x000a0;months, the 2-year survival rate is 27.2%, and disease recurrence is universal, with virtually all patients dying within 1.5&#x000a0;years after relapse [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Thus, there is a clear need for novel therapeutic modalities.</p><p id="Par38">Dendritic cell (DC)-based, active anti-tumoral cellular immunotherapy aims at generating autologous cytotoxic effector T cells, which kill tumor cells specifically. Because of their central role in initiating such T-cell responses, DC are used as cellular adjuvant for application of tumor antigens in tumor vaccines [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]: Patients are vaccinated with tumor antigen-loaded DC, with the concept that they will migrate to local lymph nodes, present tumor antigen-derived peptides on human leukocyte antigens (HLA) and initiate an anti-tumoral T-cell response.</p><p id="Par39">DC-based vaccination therapy was first applied in a clinical trial in 1996 for B-cell lymphoma [<xref ref-type="bibr" rid="CR6">6</xref>], but only in 2006 has the clinical efficacy of this approach been proven in a phase III trial for hormone-refractory prostate cancer patients [<xref ref-type="bibr" rid="CR7">7</xref>]. For GBM, since the first case report in 2000 [<xref ref-type="bibr" rid="CR8">8</xref>], 38 studies and case reports have been published, initially applying DC vaccination in recurrent disease, but more recently as part of first-line therapy in newly diagnosed patients as well [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. Close to 500 GBM patients have been treated with DC vaccination in these studies, with the age of patients ranging from 1 to 80&#x000a0;years.</p><p id="Par40">Previous studies have documented feasibility and safety. There have been no reports of severe side effects (&#x02265;&#x02009;grade 3) attributable to vaccination, except for one patient with gross residual tumor after surgery, who suffered from peritumoral edema, which was controllable by glucocorticoids [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Frequently observed mild and easily controllable toxicities (&#x02264;&#x02009;grade 2), which may be attributable to DC vaccination, have been injection site reactions with itching, pain, erythema, induration and lymph node swelling as well as flu-like symptoms, fever, fatigue, myalgia, headache, edema and meningeal irritation. Thus, overall toxicity of DC vaccination therapy is limited, and vaccination has also no severe impact on the quality of life of patients. Indeed, the quality of life of patients has been reported to remain stable during vaccination therapy [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] or even to improve [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par41">Induction of antigenic, target-directed immune responses have been observed in the course of vaccination, with detection of interferon (IFN)-&#x003b3; responses being most informative [<xref ref-type="bibr" rid="CR25">25</xref>], but anti-tumoral cytotoxic responses [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>] and an increase in tetramer positive cytotoxic T cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] have been reported as well. Several studies identified immunological responders based on delayed-type hypersensitivity-like reactions [<xref ref-type="bibr" rid="CR20">20</xref>], IFN-&#x003b3; responses [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] or cytotoxic responses [<xref ref-type="bibr" rid="CR19">19</xref>] and reported longer survival times of responders [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Moreover, long-term survivors with durable IFN-&#x003b3; responses have been identified [<xref ref-type="bibr" rid="CR43">43</xref>]. Such associations of anti-tumoral immunity with survival are in line with the proposed mechanism of action of vaccination therapy and strong arguments for the efficacy of this type of active immunotherapy in GBM.</p><p id="Par42">Prolonged survival of vaccinated patients has been reported compared to matched or historic controls [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. In a recent meta-analysis of 9 studies, Cao et al. [<xref ref-type="bibr" rid="CR47">47</xref>] concluded that vaccination significantly improves OS (1&#x02013;5&#x000a0;years) as well as PFS rates (1&#x02013;4&#x000a0;years), e.g., OS rates at 4&#x000a0;years were 20% and 1%, at 5&#x000a0;years 14% and 0% for vaccinated and non-vaccinated patients, respectively.</p><p id="Par43">For newly diagnosed GBM, in a recent randomized phase II trial with 34 patients [<xref ref-type="bibr" rid="CR35">35</xref>], the OS rate at 24&#x000a0;months (44.4%) as well as the median OS (31.9&#x000a0;months) of the vaccination group compared favorably to the control group (18.8%; 15.0&#x000a0;months). In another controlled study including 25 patients, median OS (17.0 vs. 10.0&#x000a0;months) as well as OS rates at 2&#x000a0;years (7.7% vs. 0%) compared favorably for the vaccinated patients [<xref ref-type="bibr" rid="CR37">37</xref>]. In 16 non-randomized studies, the median OS of newly diagnosed GBM patients ranged from 11.0 to 38.4&#x000a0;months [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], with one [<xref ref-type="bibr" rid="CR10">10</xref>] of the three studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] reporting the lowest median OS (11.0&#x02013;15.0&#x000a0;months), nevertheless describing an improved OS compared to matched controls (15.0 vs. 8.4&#x000a0;months).</p><p id="Par44">Thus, results of previous DC vaccination trials have been encouraging, although they cannot yet provide robust evidence of clinical efficacy. Moreover, DC vaccination can be easily integrated into the current first-line therapy, and there is a rational for such an integration besides retaining a therapy with proven clinical efficacy for the patients; it may allow exploiting synergies between the treatment modalities: (1) after resection/radio-/chemotherapy, patients are in a state of minimal residual disease, which is probably beneficial for immunotherapy because of the lower tumor load and the depletion of immunosuppressive cells [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], (2) TMZ appears to improve immunological responsiveness [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>], probably by reducing regulatory T cells (Treg) [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] and interfering with their recruitment to the tumor [<xref ref-type="bibr" rid="CR52">52</xref>], (3) the recovering lymphocyte compartment after chemotherapy appears to be beneficial for induction of anti-tumoral responses [<xref ref-type="bibr" rid="CR53">53</xref>], (4) dying tumor cells after radiochemotherapy result in local pro-inflammatory conditions and a release of tumor antigens, which could improve homing of tumor-specific effector T cells to the brain tumor [<xref ref-type="bibr" rid="CR54">54</xref>] and (5) there is an increased responsiveness to TMZ chemotherapy after DC vaccination [<xref ref-type="bibr" rid="CR17">17</xref>]. Therefore, it now appears mandatory to determine efficacy of DC vaccination in a randomized, controlled trial on a large cohort of newly diagnosed GBM patients with standard therapy as comparator. If the hypothesis is proven correct that DC vaccination as add-on to the standard therapy in GBM significantly prolongs survival with acceptable toxicity and without significantly reducing the quality of life of patients, this trial will contribute to its implementation as therapy in newly diagnosed GBM. Otherwise, clarification of efficacy is also urgently needed for counseling GBM patients, who are aware of the apparently promising results of this therapeutic approach.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par45">This is a national, prospective, multicenter, open-label, randomized phase II study with two parallel groups, with the participating hospitals being located in the state of North Rhine-Westphalia in the proximity of D&#x000fc;sseldorf (a list of participating centers can be obtained from the sponsor or the registry). In the active recruitment period of 30&#x000a0;months, 136 patients with newly diagnosed, isocitrate dehydrogenase (IDH) wildtype, primary GBM [<xref ref-type="bibr" rid="CR55">55</xref>] will be randomized at a 1:1 ratio after near-complete resection and successful production of tumor lysate. For a patient to be enrolled, all eligibility criteria (see below) must be met and free vaccine production capacity has to be available (enrollment may have to be paused). Enrollment of a patient is initiated by an investigator submitting by fax the Randomization Request Form to the Coordination Center for Clinical Trials, which will perform the randomization and inform the investigator of the outcome and allocation of the patient to the control or the vaccination arm of the study. The randomization list has been generated by the Coordination Center for Clinical Trials, using randomly selected block sizes of 4, 6, 8 and 12 patients. It will be centrally applied with concealment by the Coordination Center for Clinical Trials. The assignment to the two groups will be stratified according to O6-methylguanine-DNA-methyltransferase promotor methylation status, because it is an independent prognostic factor in TMZ chemotherapy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par46">All patients will receive the current standard of care with proven clinical efficacy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR57">57</xref>] for newly diagnosed GBM consisting of (1) FGS, (2) fractionated RT (60&#x000a0;Gy, 2&#x000a0;Gy/day, 5/7 days, 6 weeks) with concurrent TMZ chemotherapy (75&#x000a0;mg/m<sup>2</sup>/day, 6 weeks) and (3) subsequent adjuvant TMZ chemotherapy (150&#x02013;200&#x000a0;mg/m<sup>2</sup>/day, days 1&#x02013;5 of 28-day&#x000a0;cycle, six&#x000a0;cycles). TMZ dose reduction due to toxicity follows standard rules: Concomitant TMZ chemotherapy will be interrupted when the absolute neutrophil count is 500&#x02013;1500/&#x003bc;l or the platelet count is 10,000&#x02013;100,000/&#x003bc;l or non-hematological toxicity grade 2 occurs. Concomitant TMZ chemotherapy will be discontinued when the absolute neutrophil count is &#x0003c;&#x02009;500/&#x003bc;l or the platelet count is &#x0003c;&#x02009;10,000/&#x003bc;l or non-hematological toxicity grade 3 or 4 occurs. Adjuvant TMZ chemotherapy dose will be reduced when the absolute neutrophil count is &#x0003c;&#x02009;1000/&#x003bc;l or the platelet count is &#x0003c;&#x02009;50,000/&#x003bc;l or non-hematological toxicity grade 3 occurs. Adjuvant TMZ chemotherapy will be discontinued when hematological and non-hematological toxicities persist despite the lowest dose of TMZ (75&#x000a0;mg/m<sup>2</sup>/day).</p><p id="Par47">In the control group, patients receive this standard treatment with proven clinical efficacy (comparator). Patients in the vaccination arm of the study will receive as add-on up to seven tumor lysate-loaded, mature DC vaccines (2&#x02013;10&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells each applied by intradermal injection): four priming vaccines in weekly intervals during the period between concomitant radiochemotherapy and adjuvant chemotherapy and three monthly boosting vaccines in the third week of the first three 28-day&#x000a0;cycles of adjuvant TMZ (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Availability of less than three vaccines is regarded as treatment failure. Vaccines will be applied irrespective of whether concomitant TMZ has to be terminated or adjuvant TMZ has to be reduced or terminated due to toxicity. Corticosteroids should be avoided or kept to a minimum 1 week before until 1 week after vaccination. In case of temporary need for high-dose corticosteroids 1 week before vaccination (&#x0003e;&#x02009;8&#x000a0;mg/day dexamethasone or equivalent), vaccination has to be postponed. Any other anti-cancer treatment, including agents with only suspected anti-cancer effects, any other investigational or experimental treatment, any other active immunotherapy or any treatment that interferes with immune function, including persistent immunosuppressive therapy (e.g., for rheumatism) should be avoided or kept to a minimum during the treatment period. If a patient misses two or more of the priming vaccinations, this is regarded as treatment failure. If one priming vaccination or one, two or all three boost vaccinations are missed, it will be attempted to add the missed vaccinations (maximum: 3) as additional boost vaccinations, always in the third week of subsequent adjuvant TMZ cycles (cycles 4&#x02013;6).<fig id="Fig1"><label>Fig. 1</label><caption><p>GlioVax study design. After resection, patients are randomized 1:1 into the vaccination and standard arms of the study. Patients in the standard arm are treated with fractionated radiotherapy (RT) and concomitant temozolomide (TMZ) chemotherapy, followed by 6&#x000a0;cycles of adjuvant TMZ. Patients in the vaccination arm receive 4 priming vaccinations and 3 boosting vaccinations with tumor-lysate-loaded, mature DC as add-on therapy to the standard therapy, between radiochemotherapy and adjuvant TMZ and in the first 3 cycles of adjuvant TMZ, respectively. The overall intervention period in both arms is 38&#x000a0;weeks, follow-up is 2 years. After screening (visits &#x02212;&#x02009;3 to &#x02212;&#x02009;1), 18 study visits (visit 0 (baseline) to visit 17) and 8 3-monthly follow-up visits are planned, to assess safety, efficacy and quality of life. Visits indicated in blue are in the vaccination arm only. Other visits are for patients in both arms of the study</p></caption><graphic xlink:href="13063_2018_2659_Fig1_HTML" id="MO1"/></fig></p><p id="Par48">Patients are informed verbally and on the basis of the informed consent form in-depth about the importance of vaccination being performed in line with the protocol. They receive the contact information of the coordinating investigator and are invited to contact him in case of any questions. Standard therapy will be performed in all participating hospitals. Production and application of vaccines will be in D&#x000fc;sseldorf only. The intervention period is 38&#x000a0;weeks, follow-up is 24&#x000a0;months. Overall, a duration of 63&#x000a0;months (first patient in to last patient out 54&#x000a0;months) is anticipated for the trial (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Visits for enrollment, treatment and assessments. After screening for eligibility and allocation (visits &#x02212;&#x02009;3 to &#x02212;&#x02009;1), 18 study visits (visits 0&#x02013;17) are planned for treatment and assessments during the treatment period, followed by 8 additional visits (visits 18&#x02013;25) during the 2-year follow-up. <sup>1</sup>Resection is performed in week 0 (visit &#x02212;&#x02009;2); <sup>2</sup>weeks 5&#x02013;10: 6 cycles of concomitant radiochemotherapy; <sup>3</sup>weeks 15, 19, 23, 27, 31, 35): 6 cycles (days 1&#x02013;5 of 28-day&#x000a0;cycle) of adjuvant temozolomide (TMZ) chemotherapy; <sup>4</sup>weeks 11&#x02013;14: 4 priming vaccinations; <sup>5</sup>weeks 17, 21, 25: 3 boost vaccinations; <sup>6</sup>weeks 16, 28, 37: magnetic resonance imaging (MRI) scans; <sup>7</sup>weeks 5, 10: clinical, clinical chemistry, hematological, hemostaseological examinations and adverse events (AE), concomitant medication and KPS assessments; <sup>8</sup>weeks 11&#x02013;14: clinical, clinical chemistry, hematological, hemostaseological examinations and AE and concomitant medication assessments; <sup>9</sup>weeks 15, 17, 21, 25, 29, 33, 38: clinical, clinical chemistry, hematological, hemostaseological examinations and AE and concomitant medication assessments; <sup>10</sup>week 10: neurological performance and quality of life assessments; <sup>11</sup>weeks 15, 29, 38: KPS, neurological performance and quality of life assessments; <sup>12</sup>tumor tissue and blood for translational research studies are sampled during resection, leukapheresis and at the 7 time points of vaccination; <sup>13</sup>pregnancy tests are performed at monthly intervals until 6&#x000a0;months after the treatment period; *vaccination arm only</p></caption><graphic xlink:href="13063_2018_2659_Fig2_HTML" id="MO2"/></fig></p><p id="Par49">A formal interim efficacy analysis will be performed when approximately 50% of the expected 87 events have occurred in the treatment and control groups combined. At the interim, a group-sequential methodology will be applied to the analysis. The O&#x02019;Brien-Fleming approach [<xref ref-type="bibr" rid="CR58">58</xref>] will be used and overwhelming efficacy will be concluded if the two-sided <italic>p</italic> value of the log-rank test for the difference in median OS between treatments is &#x0003c;&#x02009;0.003. The decision to close the trial based on overwhelming or inferior efficacy of vaccination will be taken by the sponsor together with the coordinating investigator after critically assessing ethical and safety aspects.</p></sec><sec id="Sec4"><title>Eligibility criteria</title><p id="Par50">All inclusion and exclusion criteria (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) will be evaluated by the local investigators (neurosurgeons and/or neuro-oncologists) and in case of residual tumor volume after surgery and diagnosis/tumor cell content of tumor sample confirmed by central neuroradiologist and neuropathologist, respectively.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Key inclusion criteria</th><th>Key exclusion criteria</th></tr></thead><tbody><tr><td>Newly diagnosed, monofocal GBM, isocitrate dehydrogenase wildtype (WHO grade IV; [<xref ref-type="bibr" rid="CR57">57</xref>]) histologically confirmed by central neuropathologist</td><td>Medical history of severe acute or chronic disease with poor prognosis, autoimmune disorder, immunodeficiency, organ allograft or prior malignancy (&#x02264;&#x02009;3 years)</td></tr><tr><td>Near-complete resection (&#x02264;&#x02009;5&#x000a0;ml residual tumor volume) confirmed by central neuroradiologist on magnetic resonance imaging (MRI) scan within 72&#x000a0;h postoperative</td><td>Infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus or <italic>Treponema pallidum</italic> or other severe infection requiring hospitalization or i.v. antibiotics or anti-viral treatment (&#x02264;&#x02009;2 weeks)</td></tr><tr><td>Patients &#x02265;&#x02009;18&#x000a0;years of age</td><td>Known allergy or intolerability to TMZ or any component of the capsules, dacarbazine, the contrast agent or the DC vaccine</td></tr><tr><td>Karnofsky performance status &#x02265;&#x02009;70%</td><td>History of bleeding diathesis or coagulopathy</td></tr><tr><td>Sterile tumor sample of &#x02265;&#x02009;150&#x000a0;mg with tumor cell frequency&#x02009;&#x02265;&#x02009;60%, as determined by central neuropathologist, available for vaccine production</td><td>Preexisting myelosuppression</td></tr><tr><td>Successful production of sterile, avital tumor lysate</td><td>Previous radiotherapy to head and neck</td></tr><tr><td>Systemic corticosteroids tapered down to &#x02264;&#x02009;2&#x000a0;mg of dexamethasone or equivalent per day within 7&#x000a0;days postoperative</td><td>Previous (&#x02264;&#x02009;6 weeks. or&#x02009;&#x02264;&#x02009;5 half-lives) treatment with specific immunostimulatory agent</td></tr><tr><td>Adequate hepatic, renal, liver and bone marrow function and blood coagulation</td><td>Previous (&#x02264;&#x02009;4 weeks) treatment with live, attenuated vaccine</td></tr><tr><td>Use of highly effective contraception</td><td>Treatment of GBM in another clinical trial with therapeutic intervention or current use of any investigational agent</td></tr><tr><td rowspan="2">Signed informed consent</td><td>Known pregnancy or breast-feeding</td></tr><tr><td>O6-methylguanine-DNA-methyltransferase promoter methylation status equivocal</td></tr></tbody></table><table-wrap-foot><p>Legend: <italic>DC</italic> dendritic cell, <italic>GBM</italic> glioblastoma multiforme, <italic>i.v.</italic> intravenous, <italic>TMX</italic> temozolomide, <italic>WHO</italic> World Health Organization</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Study endpoints</title><p id="Par51">The primary objective of the study is to determine whether survival of newly diagnosed GBM patients treated with lysate-loaded, mature DC vaccines as add-on to the standard of care is superior to the treatment with the standard of care alone. The primary efficacy endpoint is OS measured from the day of surgery until death. Secondary objectives are comparing (1) progression-free survival (PFS), (2) 6-, 12- and 24-month OS and PFS rates, (3) the safety profile, (4) overall and neurological performance and (5) the quality of life between the two treatment groups.</p><p id="Par52">Following the baseline visit, 17 visits during the treatment period of 38&#x000a0;weeks and 8 visits during the 2-year follow-up period have been planned to assess primary and secondary endpoints. Study visits have been scheduled as close as possible to those of the standard treatment to limit any additional burden for the patients. Tumor progression will be assessed by magnetic resonance imaging (MRI) according to modified RANO (response assessment in neuro-oncology) criteria [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Following standard protocol, MRI examinations after the 72-h post-surgical MRI scan will start in week 16 (6&#x000a0;weeks after completion of radiochemotherapy) and will be performed thereafter in 3-monthly intervals during the treatment as well as in the follow-up periods.</p><p id="Par53">At each visit (for visit plan see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), clinical examinations as well as laboratory assessments will be performed to monitor safety, with toxicity coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events 4.03 (CTCAE 4.03). All adverse events (AE) occurring in the course of the trial will be documented. Each AE is rated by the investigator whether a correlation with the trial drug can be assumed (adverse drug reaction; ADR) or not. All severe adverse events (SAE), irrespective of whether associated with the trial drug (severe adverse drug reaction; SADR) or not and whether rated by the coordinating investigator as unexpected or a suspected unexpected severe drug reaction (SUSAR) will be reported to the sponsor within 24&#x000a0;h, and every SUSAR will be reported by the sponsor to the National Competent Authority and the Ethics Committee. Pregnancies are documented on a separate Pregnancy Report Form and reported to the sponsor immediately after learning of the pregnancy.</p><p id="Par54">The Karnofsky performance status, neurological performance status (Minimal Mental State Examination-2; [<xref ref-type="bibr" rid="CR61">61</xref>]), quality of life (EORTC QLQ-C30 and QLQ-BN20 questionnaires; [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]) and psycho-oncological distress (Distress Thermometer [<xref ref-type="bibr" rid="CR64">64</xref>] and Hospital Anxiety and Depression Scale [<xref ref-type="bibr" rid="CR65">65</xref>] will be assessed.</p><p id="Par55">Patients withdrawn from the trial prematurely by the investigator or at their own request are asked to participate in the Termination Visit (clinical, clinical chemistry, hematological, hemostaseological examinations, MRI, AE assessment, overall and neurological performance, quality of life) and to the 3-monthly follow-up according to study protocol until the end of the follow-up period. At a minimum, all AE should be followed until they are fully and permanently resolved or have stabilized. If the patient withdraws or declines consent for disclosure of future information, no further evaluations will be performed, and no additional data will be collected, but the use of any data collected before of the withdrawal will be retained, to be used further as may be necessary, e.g., to assess efficacy and safety.</p><p id="Par56">Safety and efficacy data will also be assessed by an independent Data Safety and Monitoring Committee (DSMC) composed of a neurosurgeon, a neuro-oncologist, a neuropathologist and a biostatistician, who had no involvement in the design of the study, are not involved in its conduct other than through their role on the DSMC, and who have no financial interest in the outcome of the study. Assessments will be based on semiannually safety reports and the interim report. The DSMC may recommend to the sponsor at any time during the trial discontinuation of the trial or modification of the protocol for safety reasons. It may also recommend to stop the trial in case of insufficient enrollment or overwhelming/inferior efficacy. The DSMC Charter provides a detailed description of the responsibilities and activities of the DSMC.</p></sec><sec id="Sec6"><title>Data management, monitoring and auditing</title><p id="Par57">All data will be collected in electronic case report forms (eCRF). The eCRF will be implemented in a Good Clinical Practice (GCP)-compliant clinical data management system with electronic data capture functionality, which provides the capability to perform the major data management activities within a consistent, auditable and integrated electronic environment (query management, data entry, data validation). Range, validity and consistency checks will be implanted in the eCRF for application during data entry. All data entry, modification or deletion will be recorded automatically in an audit trail indicating the original value, the new value, the reason for change, who made the change and when the change was made. A digital signature is implemented and included in the audit trail. Periodically, central monitoring of the data is performed and actions are taken to ensure data quality (queries, re-training). Implementation of the eCRF has been performed by data managers in cooperation with biostatisticians from the Coordination Center for Clinical Trials. All procedures are documented in the protocol and in the Data Management Manual.</p><p id="Par58">Source data remain in the respective hospital information system. Source documents, in particular documents with plain-text names of the participating patients, are kept under strict control of the investigator at the trial site. They will not be transferred to the sponsor or other persons that are not authorized by the patient in the data protection declaration part of the informed consent form. Data recorded in the eCRF are pseudonymized; the Patient Identification List is kept under strict control at the individual trial sites.</p><p id="Par59">Periodic monitoring of the trial will be performed on site in the trial centers by clinical research associates to ensure the safety of the trial participants, the trial itself as well as the correctness of the collected data. They will check the availability of the patient&#x02019;s informed consent, adherence to eligibility criteria, adherence to treatment according to the trial protocol, safety parameters and completeness of the trial documents in the trial center. The monitor confirms completed source data verification by electronic signature in the eCRF. Monitoring is described in detail in the Monitoring Manual. The on-site trial monitoring is combined with central monitoring with regular data checks.</p><p id="Par60">To ensure sponsor oversight, audits will be performed by an independent auditor at the sponsor&#x02019;s request. Especially, the vaccine production and its documentation as well as the correct delivery of the tumor and blood samples will be audited. In case of non-compliance of the study centers an audit can also be performed.</p></sec><sec id="Sec7"><title>Advanced therapy medicinal product: DC vaccine</title><p id="Par61">The DC vaccines for the GlioVax trial are produced specifically for each patient according to established standard operating procedures with production permission by the local authorities. The vaccines consist of two autologous cellular components: (1) tumor lysates as a whole-cell source of tumor antigens and (2) monocyte-derived, mature DC.</p><p id="Par62">Lysates are produced from autologous tumor material of the patients obtained from fluorescein-guided surgery (FGS). FGS is an established standard surgical procedure for GBM [<xref ref-type="bibr" rid="CR57">57</xref>]. Because the &#x0201c;solid&#x0201d; part of the tumor can be identified intraoperatively, high-purity tumor material can be obtained, and only samples with a tumor cell content of at least 60% are used for vaccine production. After resection, tumor material is stored frozen at &#x02212;&#x02009;80&#x000a0;&#x000b0;C until processing, which involves mechanical dissection and repeated freeze/thaw cycles to generate the lysate.</p><p id="Par63">DC are generated from monocytes enriched immunomagnetically from non-mobilized leukapheresis products. A two-step serum-free culture system is used, to successively generate immature and mature DC [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Monocytes are cultured for 6 days in Teflon bags in the presence of granulocyte-macrophage-colony-stimulating factor and interleukin-4 to generate immature DC, which are loaded with tumor antigens by adding the autologous tumor lysate to the cultures. Maturation of DC is induced during an additional 3-day culture period, using the classical pro-inflammatory maturation cocktail described by Jonuleit et al. [<xref ref-type="bibr" rid="CR68">68</xref>], containing tumor necrosis factor &#x003b1;, interleukin-1&#x003b2;, interleukin-6 and prostaglandin E2, which allows generation of CD83+, fully mature DC with high purity and potent T-cell stimulatory and T<sub>H</sub>1-polarizing activity. After ex-vivo generation of the tumor-lysate-loaded, mature DC, they are stored frozen until the day of application, on which they are thawed, washed, resuspended in 0.9% sodium chloride solution and transferred into a 1-ml syringe for immediate application.</p></sec><sec id="Sec8"><title>Sample size considerations and statistical analysis</title><p id="Par64">The sample size calculation is based on the primary outcome OS. A median OS of 14.6&#x000a0;m has been reported for the control intervention [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In eight recent smaller phase I/II trials on newly diagnosed GBM treated with lysate-loaded DC as add-on to radiochemotherapy, median OS of 35.9&#x000a0;months [<xref ref-type="bibr" rid="CR32">32</xref>], 34.4&#x000a0;months [<xref ref-type="bibr" rid="CR17">17</xref>], 31.9&#x000a0;months (control group 15.0&#x000a0;months) [<xref ref-type="bibr" rid="CR35">35</xref>], 30.5&#x000a0;months [<xref ref-type="bibr" rid="CR45">45</xref>], 28.0&#x000a0;months [<xref ref-type="bibr" rid="CR30">30</xref>], 27.4&#x000a0;months [<xref ref-type="bibr" rid="CR38">38</xref>], 24.0&#x000a0;months [<xref ref-type="bibr" rid="CR28">28</xref>], 18.4&#x000a0;months [<xref ref-type="bibr" rid="CR34">34</xref>] and 17.0&#x000a0;months (control group 10.5&#x000a0;months) [<xref ref-type="bibr" rid="CR37">37</xref>] have been reported. Based on a critical appraisal of these data, taken into consideration potential treatment dilution effects for the results from the smaller phase I/II trials, we have assumed a prolongation of OS of 12&#x000a0;months for the vaccination group (OS 26.6&#x000a0;months). When the sample size in each group is 61, with a total number of events required of 87, a 0.050-level two-sided log-rank test for equality of survival curves will have 80% power to detect the difference between a median OS in the control group of 14.6&#x000a0;months vs. 26.6&#x000a0;months in the test group (hazard ratio for death, 0.55).</p><p id="Par65">In order to compensate for dropouts (i.e. patients dropping out prior to 24&#x000a0;months without having an event) the total sample size is planned at 136 patients (i.e. an approximately&#x02009;10% dropout rate). Mainly due to a tumor content of samples for vaccine production below 60% or unsterile tumor material (7/37 (19%); determined at the Institute for Transplantation Diagnostics and Cell Therapeutics, D&#x000fc;sseldorf) or residual tumor volume above 5&#x000a0;ml upon radiological evaluation (17%; [<xref ref-type="bibr" rid="CR57">57</xref>]), it is anticipated that approximately 35% of GBM patients will fail to meet inclusion/exclusion criteria after resection. Therefore, 210 patients have to be screened to allow for enrollment of 136 patients in the trial.</p><p id="Par66">Each year, about 450&#x02013;500 patients with newly diagnosed GBM are treated in the participating centers, of which about 280 (60%) would fulfill the inclusion/exclusion criteria of the trial. It is anticipated that about 260 of these patients would agree to participate and that it would be possible to recruit 210 patients in the 30-month recruitment period. Thus, recruitment of 136 patients seems feasible. The recruitment rate would be about one patient/center/month and centers would have to assess one to two/patients/month for eligibility.</p><p id="Par67">Evaluation of results will be based on the Statistical Analysis Plan. Efficacy is measured by OS computed from the day of surgery until event or censored at last follow-up according to the Kaplan-Meier method with two-sided log-rank statistics for comparison. Primary efficacy analysis will be based on the intention-to-treat population; patients lost to follow-up are censored at the time of last contact. If required, a model-based Bayesian analysis for imputation of missing data will be used, and missing values imputed using the posterior predictive distribution of the model. In addition, a sensitivity analysis based on the per-protocol population will be performed.</p><p id="Par68">All patients will be evaluated for safety; assessment of safety will be based on descriptive and explorative methods. For explorative analyses of secondary endpoints, classical statistical tests will be applied (e.g., log-rank test for survival data (PFS), chi-square/Fischer&#x02019;s exact test for categorical data and <italic>t</italic> test/Mann-Whitney <italic>U</italic> test for continuous data). In addition, 95% confidence intervals will be calculated when applicable.</p><p id="Par69">A Cox regression model will be used for explorative analysis of overall survival and progression-free survival with the covariates (1) treatment group, (2) recursive partitioning analysis classes I&#x02013;IV as defined by Mirimanoff et al. [<xref ref-type="bibr" rid="CR69">69</xref>] and de Vleeschouwer et al. [<xref ref-type="bibr" rid="CR70">70</xref>], which already have been documented to influence outcome of standard as well as of vaccination therapy, the prognostic markers, (3) MGMT promotor methylation status, (4) extent of resection (complete vs. near-complete), (5) age, (6) center, (7) dexamethasone medication and (8) the therapeutic intervention in case of tumor progression. Subgroups of vaccinated patients will also be defined based on their immunological responsiveness as well as immunosuppressive scores (see below).</p></sec></sec><sec id="Sec9"><title>Discussion</title><sec id="Sec10"><title>Trial design</title><p id="Par70">The trial design attempts to minimize parameters, which have been identified to affect clinical and immunological outcome, in order to generate informative results on efficacy of DC vaccination in GBM. Only adults with confirmed newly diagnosed primary GBM after near-complete resection will be included, with all patients undergoing standard radio/TMZ chemotherapy. Moreover, DC vaccination with high-purity, tumor-lysate-loaded, mature DC will be fully integrated into standard therapy.</p><p id="Par71">Randomization will be the main method against bias. DC vaccines are produced specifically for the individual patient, using the patient&#x02019;s own tumor and leukocytes as starting material. We have considered it to be unethical to subject the patients of the control group to the potential risks and the stress of leukapheresis merely for blinding purposes. Thus, only patients of the vaccination group are subjected to leukapheresis and, therefore, there will apparently be different procedures applied to patients in the control and vaccination groups, which also requires different logistics. Therefore, blinding the study has not been possible.</p></sec><sec id="Sec11"><title>Tumor-induced immunosuppression</title><p id="Par72">After activation by the DC, effector T cells can cross the blood-brain barrier and exert their effector function in the brain [<xref ref-type="bibr" rid="CR71">71</xref>], with a contribution of luminal antigen presentation by endothelial cells to identify the specific site for effector T cells to enter the brain parenchyma [<xref ref-type="bibr" rid="CR54">54</xref>] and a final tuning of T-cell effector functions by the brain microenvironment [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Thus, the basic pre-requisites for DC vaccination therapy of GBM are in place, and numerous animal studies could confirm that it is a a promising therapeutic approach in brain tumors [<xref ref-type="bibr" rid="CR73">73</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>]. However, there is also tumor-induced immunosuppression, and several contributing mechanisms have been identified [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>], including an increase in regulatory T cells in the blood as well as in the tumor microenvironment, which is associated with impaired T-cell responsiveness [<xref ref-type="bibr" rid="CR80">80</xref>]. Such immunosuppression may hamper DC vaccination therapy and, therefore, has to be overcome, to improve or even allow efficacy. In GBM, it correlates with the size of the tumor, and surgical cytoreduction can restore T-cell responsiveness, at least partially [<xref ref-type="bibr" rid="CR81">81</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>]. Certain chemotherapeutics, including TMZ, which is used in the standard treatment of GBM, have also been reported to reduce T<sub>reg</sub> in the periphery as well as in the tumor [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>], which might be important to increase the vaccine efficacy [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Thus, there is a rationale to maximally reduce the tumor burden, prior to DC vaccination therapy and combine it with TMZ chemotherapy.</p></sec><sec id="Sec12"><title>Lysate as a source of tumor antigens</title><p id="Par73">For the GlioVax trial, autologous tumor lysates are used as a whole-tumor cell source of tumor antigens. Even when high-purity tumor tissue is collected by FSG, there is an abundance of normal self-proteins in tumor lysates. Nevertheless, induction of autoimmunity or other severe side effects attributable to the use of lysates for vaccine production have not been reported. Therefore, lysates can be considered a safe source of tumor antigens.</p><p id="Par74">Lysates most likely will contain multiple tumor antigens, which are present in the individual tumor of a patient (including the various cellular subsets within the tumor), i.e. the patient&#x02019;s full antigenic repertoire, ensuring antigenic diversity, thereby reducing the risk of escape of tumor-antigen-loss variants [<xref ref-type="bibr" rid="CR87">87</xref>]. Since the respective proteins are endogenously processed in the DC, presentation on HLA-class I and II molecules is possible and independent of the HLA type of the patient, thereby allowing induction of cytotoxic as well as T<sub>H-</sub>responses at the same time, which is a pre-requisite for the development of an efficient cytotoxic T-cell response. Furthermore, lysate may provide in addition to the tumor antigens the necessary signals for guiding effector T cells to the brain [<xref ref-type="bibr" rid="CR88">88</xref>]. Whether lysates are superior to molecularly defined tumor antigens in inducing anti-tumoral immune responses or more beneficial clinically in GBM is currently unknown. However, Neller et al. concluded from the analysis of 173 published immunotherapy trials on various tumor entities, including melanoma, renal cell and hepatocellular carcinomas, lung, prostate, breast, colorectal, cervical, pancreatic and ovarian cancers, a higher objective response rate (8.1% vs. 3.6%) when whole-tumor-cell antigens compared to molecularly defined tumor antigens were used [<xref ref-type="bibr" rid="CR89">89</xref>]. Therefore, lysates represent an immunologically potent source of tumor antigens.</p></sec><sec id="Sec13"><title>Maturation state of DC</title><p id="Par75">In the GlioVax trial, mature DC rather than immature or semi-mature DC are used as vaccine cells, because (1) they have potent T-cell stimulatory activity [<xref ref-type="bibr" rid="CR67">67</xref>], (2) they polarize responses towards T-helper cell (T<sub>H</sub>1) [<xref ref-type="bibr" rid="CR67">67</xref>], which is required for efficient induction of effector cytotoxic T cells [<xref ref-type="bibr" rid="CR90">90</xref>], (3) they express CC-motive chemokine receptor type 7 [<xref ref-type="bibr" rid="CR67">67</xref>]), which is required for lymph node homing [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>], (4) they are phenotypically stable upon withdrawal of cytokines [<xref ref-type="bibr" rid="CR67">67</xref>], (5) they are resistant against immunosuppressive cytokines like interleukin(IL)-10 or transforming growth factor(TGF)-&#x003b2;2, which may be produced by the tumors [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>] and (6) only immature and semi-mature DC, but not fully mature DC have been implicated in tolerance induction [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>], which would be detrimental to the intended induction of anti-tumoral immune responses. Indeed, Yamanaka et al., who used mature as well as immature DC in their study, reported a trend towards a better outcome in GBM patients vaccinated with the mature DC [<xref ref-type="bibr" rid="CR20">20</xref>] and de Vries and colleagues reported that tumor-antigen-loaded, mature DC are superior to immature DC in the induction of immunological responses in melanoma patients [<xref ref-type="bibr" rid="CR97">97</xref>]. Moreover, Dhodapkar et al. showed a decline of the influenza-matrix-peptide-specific T-cell response in healthy individuals after vaccination with matrix-peptide-loaded, immature DC and urge caution with the use of immature DC to enhance tumor immunity [<xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec14"><title>Route of vaccine administration</title><p id="Par76">Depending on the route of application, DC can be detected in different organs. Intravenous application results in a rapid enrichment in liver, lung and kidney, but is highest in spleen, whereas after subcutaneous application, there is a marked accumulation of DC in the draining lymph nodes, with a preferential paracortical localization in the T-cell areas [<xref ref-type="bibr" rid="CR99">99</xref>]. When intradermal application is used instead, even more DC reach the T-cell areas of lymph nodes in mice [<xref ref-type="bibr" rid="CR100">100</xref>] as well as in humans [<xref ref-type="bibr" rid="CR101">101</xref>], with only mature, but not immature DC, efficiently migrating to the lymph nodes in melanoma patients [<xref ref-type="bibr" rid="CR102">102</xref>], probably due to their expression of the CC-motive chemokine receptor 7, which is missing on immature DC [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. DC can be detected already after 30&#x000a0;min in the lymph nodes; they are at a maximum after 48&#x000a0;h, and they appear to persist for up to 14&#x000a0;days [<xref ref-type="bibr" rid="CR103">103</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref>]. Although only 4% of injected DC may reach the lymph nodes, this appears to be sufficient for effective induction of anti-tumoral immune responses [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Due to these advantages, intradermal application of DC vaccines is used in the GlioVax trial.</p></sec><sec id="Sec15"><title>MRI and pseudoprogression</title><p id="Par77">Standard radiochemotherapy of GBM may result in a transient increase in contrast enhancement in a large fraction of patients, which will subside eventually without any change in therapy [<xref ref-type="bibr" rid="CR59">59</xref>]. Therefore, early MRI diagnostics at week 10 after completion of radiochemotherapy is not feasible. Similarly, immunotherapy may result in inflammatory reactions, which mimic tumor progression and may even include the appearance of &#x0201c;new lesions&#x0201d; on MRI scans [<xref ref-type="bibr" rid="CR60">60</xref>]. This pseudoprogression, irrespective of whether due to standard radiochemotherapy or immunotherapy, is difficult to differentiate from true tumor progression. Moreover, immunotherapy may result in delayed responses, i.e. patients may still benefit from therapy although showing signs of progressive disease initially [<xref ref-type="bibr" rid="CR60">60</xref>]. To minimize premature declaration of tumor progression and discontinuation of therapy, in the situation of suspected progression, thus when patients meet the radiological RANO criteria for progression initially, patients may continue study medication until progression has been confirmed on a subsequent MRI scan performed within 4&#x02013;6&#x000a0;weeks [<xref ref-type="bibr" rid="CR59">59</xref>]. However, there still may be uncertainty regarding progression. Due to the sometimes long-lasting nature of particularly immune-related effects, distinguishing progression from pseudoprogression unequivocally can require a prolonged (&#x02265;&#x02009;3&#x000a0;months) observation period as summarized by Okada et al. [<xref ref-type="bibr" rid="CR60">60</xref>]. Therefore, subsequent confirmatory MRI scans in 4&#x02013;6-week intervals will be performed and patients can continue study medication as long as the clinical and neurological status of the patient has not been worsening substantially and the study medication is well tolerated, does not interfere with therapeutic interventions for imminent complications, and the investigator assesses an overall possible clinical benefit [<xref ref-type="bibr" rid="CR60">60</xref>]. Re-operation will be considered, to allow for final histological confirmation of tumor progression [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], if the suspected lesion if surgically accessible and it is the investigator&#x02019;s medical judgement that the patient may benefit from re-operation as reported previously [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. The use of additional imaging techniques (e.g., fluoroethyl-tyrosine positron-emission tomography (FET-PET)) to confirm MRI findings is also possible. The exact time of progression is defined retrospectively, when pseudoprogression and pseudoresponses can be excluded. Further treatment in case of progression is at the discretion of the investigator.</p></sec><sec id="Sec16"><title>Translational research program</title><p id="Par78">GBM-mediated immunosuppression may interfere with the development of potent anti-tumor immune responses and, thus, could be inversely correlated with clinical and immunological outcome of DC vaccination [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Moreover, detection of induction of anti-tumoral immune responses after vaccination and superior clinical outcome in immunological responders compared to non-responders would be in line with the proposed mechanism of action of DC vaccination therapy and could be a strong argument to mechanistically support the efficacy of this type of active immunotherapy in GBM. Therefore, our translation research program aims to identify immunological responders and non-responders within the group of vaccinated patients and to evaluate the association between individual anti-tumor immune responses, the degree of peripheral and local immunosuppression before, during and after the vaccination procedure, and clinical outcome.</p><p id="Par79">At defined time points during priming and boost vaccination, phenotypical and functional analysis of peripheral blood mononuclear cells (PBMC) will be performed. Multicolor flow cytometric analysis will focus on the assessment of the frequencies of CD4+ and CD8+ T-cell subsets including regulatory T cells, natural-killer-cell subsets and myeloid-derived suppressor cells (MDSC) and the expression of PD-1, PD-L1, CTLA-4 and CD107a [<xref ref-type="bibr" rid="CR112">112</xref>&#x02013;<xref ref-type="bibr" rid="CR114">114</xref>]. Furthermore, interferon (INF)-&#x003b3; ELISPOT and qPCR responses of peripheral blood mononuclear cells (PBMC) and multicytokine responses (IFN-&#x003b3;, IL-2, IL-10, TGF-&#x003b2;2, IL-17) in patient serum and conditioned media of specifically restimulated cells in the course of vaccination will be assessed. In addition, we will try to establish short-term cultured tumor cell lines from individual patients that will be used as targets for GBM-specific cytotoxic responses in CD107a degranulation assays [<xref ref-type="bibr" rid="CR115">115</xref>].</p><p id="Par80">For selected HLA-A*0201- and HLA-A*2402-positive immunological responders, we will further attempt to identify the target antigen of the anti-GBM immune response. Tetramer analysis and INF-&#x003b3; responses towards molecularly defined antigens (e.g., EphA2, MAGE1, HER2, TRP2, IL-13R2, EGFRvIII, survivin, CMVp65 peptides and the IMA950 targets [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>] will be performed after stimulation of PBMC with peptide-loaded and unloaded autologous DC. In addition, we will make use of selected Peptivators&#x000ae; (Miltenyi Biotec, Bergisch Gadbach, Germany) in non-HLA-A*0201 or non-HLA-A*2404 patients.</p><p id="Par81">Moreover, tumor tissue will be assessed by immunohistochemistry and tissue microarrays to determine local immunosuppressive factors in vaccinated patients. Analysis will include, but is not necessarily limited to, the frequency of regulatory T cells and MDSC and the expression levels of TGF-&#x003b2;2, IL-10, indolamin-2,3-dioxigenase, PD-L1 and arginin-1. If surgical resection is performed at the time of progression, tumor material will be reanalyzed as mentioned above to evaluate whether the composition and phenotype of the tumor microenvironment at baseline and after treatment correlate with clinical efficacy (Additional file <xref rid="MOESM1" ref-type="media">1</xref>).</p></sec></sec><sec id="Sec17"><title>Trial status</title><p id="Par82">Protocol version: GlioVax_Pr&#x000fc;fplan_V02_F, 01.08.2017.</p><p id="Par83">Approval by the national regulatory authority (Paul-Ehrlich Institute): #3011/01.</p><p id="Par84">Patient recruitment is planned for January 2018.</p></sec><sec sec-type="supplementary-material"><title>Additional file</title><sec id="Sec18"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2018_2659_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOCX 63&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADR</term><def><p id="Par7">Adverse drug reaction(s)</p></def></def-item><def-item><term>AE</term><def><p id="Par8">Adverse event(s)</p></def></def-item><def-item><term>CTCAE</term><def><p id="Par9">Common terminology criteria for adverse events</p></def></def-item><def-item><term>DC</term><def><p id="Par10">Dendritic cell(s)</p></def></def-item><def-item><term>DSMC</term><def><p id="Par11">Data Safety and Monitoring Committee</p></def></def-item><def-item><term>eCRF</term><def><p id="Par12">Electronic case report form(s)</p></def></def-item><def-item><term>FET-PET</term><def><p id="Par13">Fluoroethyl-tyrosine positron emission tomography</p></def></def-item><def-item><term>FGS</term><def><p id="Par14">Fluorescence-guided surgery</p></def></def-item><def-item><term>GBM</term><def><p id="Par15">Glioblastoma multiforme</p></def></def-item><def-item><term>GCP</term><def><p id="Par16">Good Clinical Practice</p></def></def-item><def-item><term>HLA</term><def><p id="Par17">Human leukocyte antigen(s)</p></def></def-item><def-item><term>IDH</term><def><p id="Par18">Isocitrate dehydrogenase</p></def></def-item><def-item><term>IFN&#x003b3;</term><def><p id="Par19">Interferon- &#x003b3;</p></def></def-item><def-item><term>IL-2, -10, -17</term><def><p id="Par20">Interleukin-2, -10, -17</p></def></def-item><def-item><term>MDSC</term><def><p id="Par21">Myeloid-derived suppressor cells</p></def></def-item><def-item><term>MedDRA</term><def><p id="Par22">Medical Dictionary for Regulatory Activities</p></def></def-item><def-item><term>MRI</term><def><p id="Par23">Magnetic resonance imaging</p></def></def-item><def-item><term>NCI</term><def><p id="Par24">National Cancer Institute</p></def></def-item><def-item><term>OS</term><def><p id="Par25">Overall survival</p></def></def-item><def-item><term>PBMC</term><def><p id="Par26">Peripheral blood mononuclear cells</p></def></def-item><def-item><term>PFS</term><def><p id="Par27">Progression-free survival</p></def></def-item><def-item><term>RANO</term><def><p id="Par28">Response assessment in neuro-oncology</p></def></def-item><def-item><term>RT</term><def><p id="Par29">Radiotherapy</p></def></def-item><def-item><term>SADR</term><def><p id="Par30">Severe adverse drug reaction(s)</p></def></def-item><def-item><term>SAE</term><def><p id="Par31">Severe adverse event(s)</p></def></def-item><def-item><term>SUSAR</term><def><p id="Par32">Suspected unexpected severe drug reaction(s)</p></def></def-item><def-item><term>TGF-&#x003b2;2</term><def><p id="Par33">Transforming growth factor-&#x003b2;2</p></def></def-item><def-item><term>T<sub>H</sub>1</term><def><p id="Par34">T-helper cell 1</p></def></def-item><def-item><term>TMZ</term><def><p id="Par35">Temozolomide</p></def></def-item><def-item><term>T<sub>reg</sub></term><def><p id="Par36">Regulatory T cell(s)</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s13063-018-2659-7) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><sec id="FPar4"><title>Funding</title><p id="Par100">The study is funded by the Federal Ministry of Education and Research (BMBF; grant 01KG1242).</p></sec><sec id="FPar5"><title>Availability of data and materials</title><p id="Par101">There are no contractual agreements, which limit access by the investigators to the final trial data. Access to data is at the discretion of the coordinating investigator and the sponsor. Results of the trial, irrespective of positive or negative outcome, will be published in peer-reviewed journals.</p></sec><sec id="FPar1"><title>Insurance</title><p id="Par85">There is a clinical trials insurance as well as a travel accident insurance covering patients participating in the trial.</p></sec><sec id="FPar2"><title>Responsibilities in the course of the trial</title><p id="Par86">The coordinating investigator (MS)/deputy coordinating investigator (MR) are responsible for the conduct of the trial, including safety evaluation and the revision of trial documents (e.g., amendment of the study protocol, including approval by the Ethics Committees and the National Regulatory Authority), if required. The co-investigator for vaccine aspects (RVS) is responsible for vaccine production. The co-investigator for immunomonitoring (MOG) is responsible for immunomonitoring. For central histopathological reviewing, central radiological reviewing, sterility and environmental hygiene monitoring, viral infectious disease testing and bacterial infectious disease testing, the appropriate departments of the University Hospital D&#x000fc;sseldorf are responsible. The Coordinating Center for Clinical Trials at the University Hospital D&#x000fc;sseldorf is responsible for project management, quality management, randomization, data management, adverse event management, monitoring and data analysis.</p><p id="Par87">In each participating center, an investigator (neurosurgeon, neurologist) is responsible for the composition and instruction of his team, for the identification, recruitment, treatment of patients and data collection adherent to the study protocol. For histopathological and radiological as well as laboratory assessments, the local departments of the participating centers are responsible.</p></sec><sec id="FPar3"><title>Sponsor</title><p id="Par88">Heinrich Heine University D&#x000fc;sseldorf.</p><p id="Par89">Universit&#x000e4;tsstr. 1.</p><p id="Par90">40,225 D&#x000fc;sseldorf.</p><p id="Par91">Germany.</p><p id="Par92">represented by.</p><p id="Par93">Prof. Dr. med. Michael C. Sabel.</p><p id="Par94">Department of Neurosurgery.</p><p id="Par95">Heinrich Heine University Hospital, D&#x000fc;sseldorf.</p><p id="Par96">Moorenstr. 5, 40,225 D&#x000fc;sseldorf, Germany.</p><p id="Par97">Phone: +&#x02009;49 (0) 211 / 81&#x02013;07334.</p><p id="Par98">Fax: +&#x02009;49 (0) 211 / 81&#x02013;04658.</p><p id="Par99">E-mail: Michael.Sabel@med.uni-duesseldorf.de</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MR is the deputy coordinating investigator. She has written the manuscript, has provided clinical expertise and contributed to the development of the protocol. OMG has contributed to the development and writing of the protocol and manuscript, particularly to the parts on immunomonitoring procedures and evaluation of tumor progression. MK has provided clinical expertise and contributed to the development of the protocol. NS is responsible for clinical project management. She has contributed to the development and writing of the protocol, particularly to the parts on study visits and the various examination procedures as well as to the patient&#x02019;s information documents. NZ is the administrative trial project manager. She has contributed to the development and writing of the protocol, particularly to the parts on adverse event management, data management and GCP as well as biometric aspects. MS is the coordinating investigator and grant holder. He has been responsible for the design and development of the protocol and the implementation of the trial. RVS is responsible for all vaccine and regulatory aspects. He shared responsibility for the protocol design and development and contributed to writing the protocol and manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par102">The study protocol has been approved by the Ethics Committee of the Medical Faculty of the Heinrich Heine University (leading Ethics Committee) and the respective Advisory Ethics Committees of the participating centers (MC-LKP-921, protocol ID: GlioVax). Written informed consent will be obtained from each patient, using the consent form approved by the Ethics Committees. It will be ensured that patients understand the procedures and risks of participating in the clinical trial, and only patients in a cognitive state to understand and sign the informed consent, indicating that they are aware of the investigational nature and the procedures of the study, will be eligible. Patients are informed that medical records may be examined by representatives of the sponsor (monitor, auditor, members of the DSMC), by the appropriate Ethics Committee members and by inspectors from the regulatory authorities. Moreover, must give their consent that tumor material and blood are transferred to the vaccine production site, processed and assessed for suitability for vaccine production, which includes infectious disease testing. Furthermore, patients agree that blood samples are used for immunomonitoring and that cells may be stored for later assessment of anti-tumoral immunity and tumor immunosuppressiveness.</p></sec><sec id="FPar7"><title>Consent for publication</title><p id="Par103">All authors have read and approved the manuscript.</p></sec><sec id="FPar8"><title>Competing interests</title><p id="Par104">The authors declare that they have no competing interests.</p><p id="Par105">Sponsor and funder are non-commercial. The sponsor keeps responsibility and oversight in the planning, initiation and conduct of the clinical trial regarding compliance to GCP and applicable laws. The funder had no role in the design of this study and will not have any role during its execution, analysis, interpretation of the data or decision to submit results.</p></sec><sec id="FPar9"><title>Publisher&#x02019;s Note</title><p id="Par106">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Bauchet</surname><given-names>L</given-names></name><name><surname>Davis</surname><given-names>FG</given-names></name><name><surname>Deltour</surname><given-names>I</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><etal/></person-group><article-title>The epidemiology of glioma in adults: a &#x0201c;state of the science&#x0201d; review</article-title><source>Neuro-Oncology</source><year>2014</year><volume>16</volume><fpage>896</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou087</pub-id><pub-id pub-id-type="pmid">24842956</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70025-7</pub-id><pub-id pub-id-type="pmid">19269895</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><etal/></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id><pub-id pub-id-type="pmid">15758009</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Cancer immunotherapy via dendritic cells</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nrc3258</pub-id><pub-id pub-id-type="pmid">22437871</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palucka</surname><given-names>K</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Dendritic-cell-based therapeutic cancer vaccines</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.004</pub-id><pub-id pub-id-type="pmid">23890062</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>FJ</given-names></name><name><surname>Benike</surname><given-names>C</given-names></name><name><surname>Fagnoni</surname><given-names>F</given-names></name><name><surname>Liles</surname><given-names>TM</given-names></name><name><surname>Czerwinski</surname><given-names>D</given-names></name><etal/></person-group><article-title>Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nm0196-52</pub-id><pub-id pub-id-type="pmid">8564842</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Schellhammer</surname><given-names>PF</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Redfern</surname><given-names>CH</given-names></name><name><surname>Nemunaitis</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3089</fpage><lpage>3094</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.5252</pub-id><pub-id pub-id-type="pmid">16809734</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Martin</surname><given-names>NA</given-names></name><name><surname>Sykes</surname><given-names>SN</given-names></name><name><surname>Bronstein</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report</article-title><source>Neurosurg Focus</source><year>2000</year><volume>e8</volume><fpage>9</fpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T</given-names></name><name><surname>Akasaki</surname><given-names>Y</given-names></name><name><surname>Irie</surname><given-names>M</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells</article-title><source>Cancer Immunol Immunother</source><year>2001</year><volume>50</volume><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1007/s002620100205</pub-id><pub-id pub-id-type="pmid">11676393</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JS</given-names></name><name><surname>Wheeler</surname><given-names>CJ</given-names></name><name><surname>Zeltzer</surname><given-names>PM</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Finger</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>842</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">11221866</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>CJ</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>4927</fpage><lpage>4933</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.9.4927</pub-id><pub-id pub-id-type="pmid">14568975</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Yajima</surname><given-names>N</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Homma</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>1172</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601268</pub-id><pub-id pub-id-type="pmid">14520441</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>DA</given-names></name><name><surname>Orme</surname><given-names>LM</given-names></name><name><surname>Neale</surname><given-names>AM</given-names></name><name><surname>Radcliff</surname><given-names>FJ</given-names></name><name><surname>Amor</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer</article-title><source>Neuro-Oncology</source><year>2004</year><volume>6</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1215/S1152851703000668</pub-id><pub-id pub-id-type="pmid">15279716</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vleeschouwer</surname><given-names>S</given-names></name><name><surname>Van Calenbergh</surname><given-names>F</given-names></name><name><surname>Demaerel</surname><given-names>P</given-names></name><name><surname>Flamen</surname><given-names>P</given-names></name><name><surname>Rutkowski</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report</article-title><source>J Neurosurg</source><year>2004</year><volume>100</volume><fpage>492</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">15287461</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T</given-names></name><name><surname>Akasaki</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Saotome</surname><given-names>H</given-names></name><etal/></person-group><article-title>Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12</article-title><source>J Immunother</source><year>2004</year><volume>27</volume><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1097/00002371-200411000-00005</pub-id><pub-id pub-id-type="pmid">15534489</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutkowski</surname><given-names>S</given-names></name><name><surname>De Vleeschouwer</surname><given-names>S</given-names></name><name><surname>Kaempgen</surname><given-names>E</given-names></name><name><surname>Wolff</surname><given-names>JE</given-names></name><name><surname>Kuhl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>1656</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602195</pub-id><pub-id pub-id-type="pmid">15477864</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>CJ</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>JS</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name></person-group><article-title>Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5316</fpage><lpage>5326</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0497</pub-id><pub-id pub-id-type="pmid">15328167</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Yong</surname><given-names>WH</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>4973</fpage><lpage>4979</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3505</pub-id><pub-id pub-id-type="pmid">15256471</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Kiertscher</surname><given-names>SM</given-names></name><name><surname>Odesa</surname><given-names>SK</given-names></name><name><surname>Kremen</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>5515</fpage><lpage>5525</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0464</pub-id><pub-id pub-id-type="pmid">16061868</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Homma</surname><given-names>J</given-names></name><name><surname>Yajima</surname><given-names>N</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>4160</fpage><lpage>4167</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0120</pub-id><pub-id pub-id-type="pmid">15930352</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>JA</given-names></name><name><surname>Yaqin</surname><given-names>S</given-names></name></person-group><article-title>Dendritic cell therapy with improved outcome in glioma multiforme&#x02014;a case report</article-title><source>J Zhejiang Univ Sci B</source><year>2006</year><volume>7</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1631/jzus.2006.B0114</pub-id><pub-id pub-id-type="pmid">16421966</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Lieberman</surname><given-names>FS</given-names></name><name><surname>Walter</surname><given-names>KA</given-names></name><name><surname>Lunsford</surname><given-names>LD</given-names></name><name><surname>Kondziolka</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas</article-title><source>J Transl Med</source><year>2007</year><volume>5</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-5-67</pub-id><pub-id pub-id-type="pmid">18093335</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vleeschouwer</surname><given-names>S</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name><name><surname>Rutkowski</surname><given-names>S</given-names></name><name><surname>Van Calenbergh</surname><given-names>F</given-names></name><name><surname>Van Loon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>3098</fpage><lpage>3104</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4875</pub-id><pub-id pub-id-type="pmid">18483377</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Laherty</surname><given-names>R</given-names></name><name><surname>Tomlinson</surname><given-names>FH</given-names></name><name><surname>Chuah</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name></person-group><article-title>Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy</article-title><source>J Clin Neurosci</source><year>2008</year><volume>15</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2007.08.007</pub-id><pub-id pub-id-type="pmid">18083572</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>CJ</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Mazer</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>XX</given-names></name><etal/></person-group><article-title>Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>5955</fpage><lpage>5964</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5973</pub-id><pub-id pub-id-type="pmid">18632651</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><name><surname>Mitchell</surname><given-names>DA</given-names></name><name><surname>Heimberger</surname><given-names>AB</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><etal/></person-group><article-title>An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme</article-title><source>Mol Cancer Ther</source><year>2009</year><volume>8</volume><fpage>2773</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0124</pub-id><pub-id pub-id-type="pmid">19825799</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardon</surname><given-names>H</given-names></name><name><surname>De Vleeschouwer</surname><given-names>S</given-names></name><name><surname>Van Calenbergh</surname><given-names>F</given-names></name><name><surname>Claes</surname><given-names>L</given-names></name><name><surname>Kramm</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours</article-title><source>Pediatr Blood Cancer</source><year>2010</year><volume>54</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">19852061</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardon</surname><given-names>H</given-names></name><name><surname>Van Gool</surname><given-names>S</given-names></name><name><surname>Lopes</surname><given-names>IS</given-names></name><name><surname>Maes</surname><given-names>W</given-names></name><name><surname>Sciot</surname><given-names>R</given-names></name><etal/></person-group><article-title>Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study</article-title><source>J Neuro-Oncol</source><year>2010</year><volume>99</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0131-y</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CN</given-names></name><name><surname>Huang</surname><given-names>YC</given-names></name><name><surname>Yang</surname><given-names>DM</given-names></name><name><surname>Kikuta</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma</article-title><source>J Clin Neurosci</source><year>2011</year><volume>18</volume><fpage>1048</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2010.11.034</pub-id><pub-id pub-id-type="pmid">21715171</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadul</surname><given-names>CE</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name><name><surname>Hampton</surname><given-names>TH</given-names></name><name><surname>Lallana</surname><given-names>EC</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy</article-title><source>J Immunother</source><year>2011</year><volume>34</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e318215e300</pub-id><pub-id pub-id-type="pmid">21499132</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name><name><surname>Ueda</surname><given-names>R</given-names></name><name><surname>Hoji</surname><given-names>A</given-names></name><name><surname>Kohanbash</surname><given-names>G</given-names></name><etal/></person-group><article-title>Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.7744</pub-id><pub-id pub-id-type="pmid">21149657</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Soto</surname><given-names>H</given-names></name><name><surname>Konkankit</surname><given-names>V</given-names></name><name><surname>Odesa</surname><given-names>SK</given-names></name><name><surname>Eskin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>1603</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2563</pub-id><pub-id pub-id-type="pmid">21135147</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>Y</given-names></name><name><surname>Oshita</surname><given-names>C</given-names></name><name><surname>Kume</surname><given-names>A</given-names></name><name><surname>Iizuka</surname><given-names>A</given-names></name><name><surname>Miyata</surname><given-names>H</given-names></name><etal/></person-group><article-title>alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><fpage>623</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-623</pub-id><pub-id pub-id-type="pmid">23270484</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardon</surname><given-names>H</given-names></name><name><surname>Van Gool</surname><given-names>SW</given-names></name><name><surname>Verschuere</surname><given-names>T</given-names></name><name><surname>Maes</surname><given-names>W</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial</article-title><source>Cancer Immunol Immunother</source><year>2012</year><volume>61</volume><fpage>2033</fpage><lpage>2044</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1261-1</pub-id><pub-id pub-id-type="pmid">22527250</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>DY</given-names></name><name><surname>Yang</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Hsu</surname><given-names>DM</given-names></name><name><surname>Lin</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial</article-title><source>World Neurosurg</source><year>2012</year><volume>77</volume><fpage>736</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2011.08.020</pub-id><pub-id pub-id-type="pmid">22120301</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwami</surname><given-names>K</given-names></name><name><surname>Shimato</surname><given-names>S</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Nakahara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele</article-title><source>Cytotherapy</source><year>2012</year><volume>14</volume><fpage>733</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.3109/14653249.2012.666633</pub-id><pub-id pub-id-type="pmid">22424217</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jie</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><etal/></person-group><article-title>Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma</article-title><source>Cell Biochem Biophys</source><year>2012</year><volume>62</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s12013-011-9265-6</pub-id><pub-id pub-id-type="pmid">21909820</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>RD</given-names></name><name><surname>de Cerio</surname><given-names>AL</given-names></name><name><surname>Inoges</surname><given-names>S</given-names></name><name><surname>Tejada</surname><given-names>S</given-names></name><name><surname>Pastor</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination in glioblastoma after fluorescence-guided resection</article-title><source>World J Clin Oncol</source><year>2012</year><volume>3</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.5306/wjco.v3.i11.142</pub-id><pub-id pub-id-type="pmid">23293753</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phuphanich</surname><given-names>S</given-names></name><name><surname>Wheeler</surname><given-names>CJ</given-names></name><name><surname>Rudnick</surname><given-names>JD</given-names></name><name><surname>Mazer</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma</article-title><source>Cancer Immunol Immunother</source><year>2013</year><volume>62</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1319-0</pub-id><pub-id pub-id-type="pmid">22847020</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vik-Mo</surname><given-names>EO</given-names></name><name><surname>Nyakas</surname><given-names>M</given-names></name><name><surname>Mikkelsen</surname><given-names>BV</given-names></name><name><surname>Moe</surname><given-names>MC</given-names></name><name><surname>Due-Tonnesen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma</article-title><source>Cancer Immunol Immunother</source><year>2013</year><volume>62</volume><fpage>1499</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1007/s00262-013-1453-3</pub-id><pub-id pub-id-type="pmid">23817721</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olin</surname><given-names>MR</given-names></name><name><surname>Low</surname><given-names>W</given-names></name><name><surname>McKenna</surname><given-names>DH</given-names></name><name><surname>Haines</surname><given-names>SJ</given-names></name><name><surname>Dahlheimer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response</article-title><source>J Immunother Cancer</source><year>2014</year><volume>2</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/2051-1426-2-4</pub-id><pub-id pub-id-type="pmid">24829761</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunn</surname><given-names>MK</given-names></name><name><surname>Bauer</surname><given-names>E</given-names></name><name><surname>Wood</surname><given-names>CE</given-names></name><name><surname>Gasser</surname><given-names>O</given-names></name><name><surname>Dzhelali</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme</article-title><source>J Neuro-Oncol</source><year>2015</year><volume>121</volume><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1635-7</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>DA</given-names></name><name><surname>Batich</surname><given-names>KA</given-names></name><name><surname>Gunn</surname><given-names>MD</given-names></name><name><surname>Huang</surname><given-names>MN</given-names></name><name><surname>Sanchez-Perez</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients</article-title><source>Nature</source><year>2015</year><volume>519</volume><fpage>366</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/nature14320</pub-id><pub-id pub-id-type="pmid">25762141</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, et al. Dendritic cell-based immunotherapy targeting Wilms&#x02019; tumor 1 in patients with recurrent malignant glioma. J Neurosurg. 2015;123(4):989&#x02013;97.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akasaki</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>T</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Koido</surname><given-names>S</given-names></name><name><surname>Ohkusa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma</article-title><source>Cancer Immunol Immunother</source><year>2016</year><volume>65</volume><fpage>1499</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1007/s00262-016-1905-7</pub-id><pub-id pub-id-type="pmid">27688162</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoges</surname><given-names>S</given-names></name><name><surname>Tejada</surname><given-names>S</given-names></name><name><surname>de Cerio</surname><given-names>AL</given-names></name><name><surname>Gallego Perez-Larraya</surname><given-names>J</given-names></name><name><surname>Espinos</surname><given-names>J</given-names></name><etal/></person-group><article-title>A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients</article-title><source>J Transl Med</source><year>2017</year><volume>15</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/s12967-017-1202-z</pub-id><pub-id pub-id-type="pmid">28499389</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>JX</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e107173</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0107173</pub-id><pub-id pub-id-type="pmid">25215607</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Woo</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma</article-title><source>Immunology</source><year>2007</year><volume>122</volume><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02680.x</pub-id><pub-id pub-id-type="pmid">17645496</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SD</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><name><surname>Park</surname><given-names>JA</given-names></name><name><surname>Sohn</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3485</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.12.060</pub-id><pub-id pub-id-type="pmid">17275143</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TG</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>SD</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model</article-title><source>Clin Vaccine Immunol</source><year>2010</year><volume>17</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1128/CVI.00292-09</pub-id><pub-id pub-id-type="pmid">19889936</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banissi</surname><given-names>C</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Carpentier</surname><given-names>AF</given-names></name></person-group><article-title>Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1627</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0671-1</pub-id><pub-id pub-id-type="pmid">19221744</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>JT</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Hussain</surname><given-names>SF</given-names></name><name><surname>DeAngulo</surname><given-names>G</given-names></name><name><surname>Prabhu</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy</article-title><source>Cancer Immunol Immunother</source><year>2008</year><volume>57</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/s00262-007-0336-x</pub-id><pub-id pub-id-type="pmid">17522861</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><name><surname>Coan</surname><given-names>A</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><etal/></person-group><article-title>Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma</article-title><source>Neuro-Oncology</source><year>2011</year><volume>13</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noq157</pub-id><pub-id pub-id-type="pmid">21149254</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>I</given-names></name><name><surname>Bernardes-Silva</surname><given-names>M</given-names></name><name><surname>Forse</surname><given-names>PA</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Liblau</surname><given-names>RS</given-names></name><etal/></person-group><article-title>An antigen-specific pathway for CD8 T cells across the blood-brain barrier</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><fpage>2023</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1084/jem.20070064</pub-id><pub-id pub-id-type="pmid">17682068</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><etal/></person-group><article-title>The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary</article-title><source>Acta Neuropathol</source><year>2016</year><volume>131</volume><fpage>803</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1545-1</pub-id><pub-id pub-id-type="pmid">27157931</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Diserens</surname><given-names>AC</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><name><surname>Hamou</surname><given-names>MF</given-names></name><name><surname>de Tribolet</surname><given-names>N</given-names></name><etal/></person-group><article-title>MGMT gene silencing and benefit from temozolomide in glioblastoma</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043331</pub-id><pub-id pub-id-type="pmid">15758010</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stummer</surname><given-names>W</given-names></name><name><surname>Pichlmeier</surname><given-names>U</given-names></name><name><surname>Meinel</surname><given-names>T</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Zanella</surname><given-names>F</given-names></name><etal/></person-group><article-title>Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial</article-title><source>Lancet Oncol.</source><year>2006</year><volume>7</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(06)70665-9</pub-id><pub-id pub-id-type="pmid">16648043</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMets</surname><given-names>DL</given-names></name><name><surname>Lan</surname><given-names>KK</given-names></name></person-group><article-title>Interim analysis: the alpha spending function approach</article-title><source>Stat Med</source><year>1994</year><volume>13</volume><fpage>1341</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1002/sim.4780131308</pub-id><pub-id pub-id-type="pmid">7973215</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Macdonald</surname><given-names>DR</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Cloughesy</surname><given-names>TF</given-names></name><name><surname>Sorensen</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1963</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.26.3541</pub-id><pub-id pub-id-type="pmid">20231676</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Finocchiaro</surname><given-names>G</given-names></name><name><surname>Gilbert</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Immunotherapy response assessment in neuro-oncology: a report of the RANO working group</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>e534</fpage><lpage>e542</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00088-1</pub-id><pub-id pub-id-type="pmid">26545842</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>&#x0201c;Mini-mental state&#x0201d;: a practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><etal/></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id><pub-id pub-id-type="pmid">8433390</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>Claassens</surname><given-names>L</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients</article-title><source>Eur J Cancer</source><year>2010</year><volume>46</volume><fpage>1033</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2010.01.012</pub-id><pub-id pub-id-type="pmid">20181476</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehnert</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>D</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>U</given-names></name></person-group><article-title>Die deutsche Version des NCCN Distress-Thermometers. Empirische Pr&#x000fc;fung eines Screening-Instruments zur Erfassung psychosozialer Belastung bei Krebspatienten</article-title><source>Zeitschrift Psychiatr Psychol Psychother</source><year>2006</year><volume>54</volume><fpage>213</fpage><lpage>223</lpage></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Buss</surname><given-names>U</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><source>HADS-D: Hospital Anxiety and Depression Scale&#x02014;Deutsche Version; Ein Fragebogen zur Erfassung von Angst und Depressivit&#x000e4;it in der somatischen Medizin</source><year>1995</year><publisher-loc>Bern</publisher-loc><publisher-name>Hans Huber Verlag</publisher-name></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Ozcan</surname><given-names>Z</given-names></name><name><surname>Steiger</surname><given-names>HJ</given-names></name><name><surname>Wernet</surname><given-names>P</given-names></name><name><surname>Sabel</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy</article-title><source>J Neurosurg</source><year>2006</year><volume>105</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3171/jns.2006.105.1.41</pub-id><pub-id pub-id-type="pmid">16874889</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorg</surname><given-names>RV</given-names></name><name><surname>Ozcan</surname><given-names>Z</given-names></name><name><surname>Brefort</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Ackermann</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical-scale generation of dendritic cells in a closed system</article-title><source>J Immunother</source><year>2003</year><volume>26</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1097/00002371-200307000-00010</pub-id><pub-id pub-id-type="pmid">12843800</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonuleit</surname><given-names>H</given-names></name><name><surname>Kuhn</surname><given-names>U</given-names></name><name><surname>Muller</surname><given-names>G</given-names></name><name><surname>Steinbrink</surname><given-names>K</given-names></name><name><surname>Paragnik</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>3135</fpage><lpage>3142</lpage><pub-id pub-id-type="doi">10.1002/eji.1830271209</pub-id><pub-id pub-id-type="pmid">9464798</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirimanoff</surname><given-names>RO</given-names></name><name><surname>Gorlia</surname><given-names>T</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><name><surname>Van den Bent</surname><given-names>MJ</given-names></name><name><surname>Kortmann</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2563</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.5963</pub-id><pub-id pub-id-type="pmid">16735709</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vleeschouwer</surname><given-names>S</given-names></name><name><surname>Ardon</surname><given-names>H</given-names></name><name><surname>Van Calenbergh</surname><given-names>F</given-names></name><name><surname>Sciot</surname><given-names>R</given-names></name><name><surname>Wilms</surname><given-names>G</given-names></name><etal/></person-group><article-title>Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination</article-title><source>Cancer Immunol Immunother</source><year>2012</year><volume>61</volume><fpage>2105</fpage><lpage>2112</lpage><pub-id pub-id-type="doi">10.1007/s00262-012-1271-z</pub-id><pub-id pub-id-type="pmid">22565485</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzascia</surname><given-names>T</given-names></name><name><surname>Di Berardino-Besson</surname><given-names>W</given-names></name><name><surname>Wilmotte</surname><given-names>R</given-names></name><name><surname>Masson</surname><given-names>F</given-names></name><name><surname>de Tribolet</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>2187</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.5.2187</pub-id><pub-id pub-id-type="pmid">12928361</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>F</given-names></name><name><surname>Calzascia</surname><given-names>T</given-names></name><name><surname>Di Berardino-Besson</surname><given-names>W</given-names></name><name><surname>de Tribolet</surname><given-names>N</given-names></name><name><surname>Dietrich</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>845</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.2.845</pub-id><pub-id pub-id-type="pmid">17617575</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>W</given-names></name><name><surname>Van Gool</surname><given-names>SW</given-names></name></person-group><article-title>Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model</article-title><source>Cancer Immunol Immunother</source><year>2011</year><volume>60</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s00262-010-0946-6</pub-id><pub-id pub-id-type="pmid">21120655</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegatta</surname><given-names>S</given-names></name><name><surname>Poliani</surname><given-names>PL</given-names></name><name><surname>Corno</surname><given-names>D</given-names></name><name><surname>Grisoli</surname><given-names>M</given-names></name><name><surname>Cusimano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice</article-title><source>Neurol Res</source><year>2006</year><volume>28</volume><fpage>527</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1179/016164106X116809</pub-id><pub-id pub-id-type="pmid">16808884</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>HT</given-names></name><name><surname>Spellman</surname><given-names>SR</given-names></name><name><surname>Jean</surname><given-names>WC</given-names></name><name><surname>Hall</surname><given-names>WA</given-names></name><name><surname>Low</surname><given-names>WC</given-names></name></person-group><article-title>Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas</article-title><source>J Neuro-Oncol</source><year>2001</year><volume>51</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1023/A:1006452726391</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Black</surname><given-names>KL</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Sykes</surname><given-names>SN</given-names></name><name><surname>DiPatre</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens</article-title><source>J Neurosurg</source><year>1999</year><volume>90</volume><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.3171/jns.1999.90.6.1115</pub-id><pub-id pub-id-type="pmid">10350260</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimberger</surname><given-names>AB</given-names></name><name><surname>Crotty</surname><given-names>LE</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Friedman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma</article-title><source>J Neuroimmunol</source><year>2000</year><volume>103</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(99)00172-1</pub-id><pub-id pub-id-type="pmid">10674985</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magana-Maldonado</surname><given-names>R</given-names></name><name><surname>Chavez-Cortez</surname><given-names>EG</given-names></name><name><surname>Olascoaga-Arellano</surname><given-names>NK</given-names></name><name><surname>Lopez-Mejia</surname><given-names>M</given-names></name><name><surname>Maldonado-Leal</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Immunological evasion in glioblastoma</article-title><source>Biomed Res Int</source><year>2016</year><volume>2016</volume><fpage>7487313</fpage><pub-id pub-id-type="doi">10.1155/2016/7487313</pub-id><pub-id pub-id-type="pmid">27294132</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razavi</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Jin</surname><given-names>BE</given-names></name><name><surname>Aujla</surname><given-names>PS</given-names></name><name><surname>Gholamin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune evasion strategies of glioblastoma</article-title><source>Front Surg</source><year>2016</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.3389/fsurg.2016.00011</pub-id><pub-id pub-id-type="pmid">26973839</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecci</surname><given-names>PE</given-names></name><name><surname>Mitchell</surname><given-names>DA</given-names></name><name><surname>Whitesides</surname><given-names>JF</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>3294</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3773</pub-id><pub-id pub-id-type="pmid">16540683</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dix</surname><given-names>AR</given-names></name><name><surname>Brooks</surname><given-names>WH</given-names></name><name><surname>Roszman</surname><given-names>TL</given-names></name><name><surname>Morford</surname><given-names>LA</given-names></name></person-group><article-title>Immune defects observed in patients with primary malignant brain tumors</article-title><source>J Neuroimmunol</source><year>1999</year><volume>100</volume><fpage>216</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(99)00203-9</pub-id><pub-id pub-id-type="pmid">10695732</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morford</surname><given-names>LA</given-names></name><name><surname>Elliott</surname><given-names>LH</given-names></name><name><surname>Carlson</surname><given-names>SL</given-names></name><name><surname>Brooks</surname><given-names>WH</given-names></name><name><surname>Roszman</surname><given-names>TL</given-names></name></person-group><article-title>T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>4415</fpage><lpage>4425</lpage><pub-id pub-id-type="pmid">9379040</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>WH</given-names></name><name><surname>Latta</surname><given-names>RB</given-names></name><name><surname>Mahaley</surname><given-names>MS</given-names></name><name><surname>Roszman</surname><given-names>TL</given-names></name><name><surname>Dudka</surname><given-names>L</given-names></name><etal/></person-group><article-title>Immunobiology of primary intracranial tumors. Part 5: correlation of a lymphocyte index and clinical status</article-title><source>J Neurosurg</source><year>1981</year><volume>54</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.3171/jns.1981.54.3.0331</pub-id><pub-id pub-id-type="pmid">7007589</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>DP</given-names></name><name><surname>Penn</surname><given-names>RD</given-names></name><name><surname>Flannery</surname><given-names>AM</given-names></name><name><surname>Harris</surname><given-names>JE</given-names></name></person-group><article-title>Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas</article-title><source>Neurosurgery</source><year>1982</year><volume>10</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">6280097</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauer</surname><given-names>OM</given-names></name><name><surname>Nierkens</surname><given-names>S</given-names></name><name><surname>Bennink</surname><given-names>E</given-names></name><name><surname>Toonen</surname><given-names>LW</given-names></name><name><surname>Boon</surname><given-names>L</given-names></name><etal/></person-group><article-title>CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo</article-title><source>Int J Cancer</source><year>2007</year><volume>121</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1002/ijc.22607</pub-id><pub-id pub-id-type="pmid">17315190</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauer</surname><given-names>OM</given-names></name><name><surname>Sutmuller</surname><given-names>RP</given-names></name><name><surname>van Maren</surname><given-names>W</given-names></name><name><surname>Jacobs</surname><given-names>JF</given-names></name><name><surname>Bennink</surname><given-names>E</given-names></name><etal/></person-group><article-title>Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>1794</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1002/ijc.23284</pub-id><pub-id pub-id-type="pmid">18076066</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>JH</given-names></name><name><surname>Heimberger</surname><given-names>AB</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Friedman</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>4722</fpage><lpage>4729</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.6963</pub-id><pub-id pub-id-type="pmid">20921459</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzascia</surname><given-names>T</given-names></name><name><surname>Masson</surname><given-names>F</given-names></name><name><surname>Di Berardino-Besson</surname><given-names>W</given-names></name><name><surname>Contassot</surname><given-names>E</given-names></name><name><surname>Wilmotte</surname><given-names>R</given-names></name><etal/></person-group><article-title>Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs</article-title><source>Immunity</source><year>2005</year><volume>22</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.12.008</pub-id><pub-id pub-id-type="pmid">15723806</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neller</surname><given-names>MA</given-names></name><name><surname>Lopez</surname><given-names>JA</given-names></name><name><surname>Schmidt</surname><given-names>CW</given-names></name></person-group><article-title>Antigens for cancer immunotherapy</article-title><source>Semin Immunol</source><year>2008</year><volume>20</volume><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2008.09.006</pub-id><pub-id pub-id-type="pmid">18951039</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Iwakabe</surname><given-names>K</given-names></name><name><surname>Sekimoto</surname><given-names>M</given-names></name><name><surname>Ohmi</surname><given-names>Y</given-names></name><name><surname>Yahata</surname><given-names>T</given-names></name><etal/></person-group><article-title>Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo</article-title><source>J Exp Med</source><year>1999</year><volume>190</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1084/jem.190.5.617</pub-id><pub-id pub-id-type="pmid">10477547</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Schaerli</surname><given-names>P</given-names></name><name><surname>Loetscher</surname><given-names>P</given-names></name><name><surname>Schaniel</surname><given-names>C</given-names></name><name><surname>Lenig</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation</article-title><source>Eur J Immunol</source><year>1998</year><volume>28</volume><fpage>2760</fpage><lpage>2769</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199809)28:09&#x0003c;2760::AID-IMMU2760&#x0003e;3.0.CO;2-N</pub-id><pub-id pub-id-type="pmid">9754563</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caux</surname><given-names>C</given-names></name><name><surname>Ait-Yahia</surname><given-names>S</given-names></name><name><surname>Chemin</surname><given-names>K</given-names></name><name><surname>de Bouteiller</surname><given-names>O</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Dendritic cell biology and regulation of dendritic cell trafficking by chemokines</article-title><source>Springer Semin Immunopathol</source><year>2000</year><volume>22</volume><fpage>345</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/s002810000053</pub-id><pub-id pub-id-type="pmid">11155441</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbrink</surname><given-names>K</given-names></name><name><surname>Wolfl</surname><given-names>M</given-names></name><name><surname>Jonuleit</surname><given-names>H</given-names></name><name><surname>Knop</surname><given-names>J</given-names></name><name><surname>Enk</surname><given-names>AH</given-names></name></person-group><article-title>Induction of tolerance by IL-10-treated dendritic cells</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>4772</fpage><lpage>4780</lpage><pub-id pub-id-type="pmid">9366401</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauer</surname><given-names>O</given-names></name><name><surname>Poschl</surname><given-names>P</given-names></name><name><surname>Lohmeier</surname><given-names>A</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name></person-group><article-title>Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2</article-title><source>J Neuro-Oncol</source><year>2007</year><volume>82</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1007/s11060-006-9274-2</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><article-title>Tolerogenic dendritic cells</article-title><source>Annu Rev Immunol</source><year>2003</year><volume>21</volume><fpage>685</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141040</pub-id><pub-id pub-id-type="pmid">12615891</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>AM</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>AD</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name></person-group><article-title>Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity</article-title><source>Front Immunol</source><year>2013</year><volume>4</volume><fpage>438</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00438</pub-id><pub-id pub-id-type="pmid">24376443</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Scharenborg</surname><given-names>NM</given-names></name><name><surname>Engelen</surname><given-names>LP</given-names></name><name><surname>Ruiter</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>5091</fpage><lpage>5100</lpage><pub-id pub-id-type="pmid">14613986</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhodapkar</surname><given-names>MV</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Krasovsky</surname><given-names>J</given-names></name><name><surname>Munz</surname><given-names>C</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1084/jem.193.2.233</pub-id><pub-id pub-id-type="pmid">11208863</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggert</surname><given-names>AA</given-names></name><name><surname>Schreurs</surname><given-names>MW</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><name><surname>Oyen</surname><given-names>WJ</given-names></name><name><surname>de Boer</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>3340</fpage><lpage>3345</lpage><pub-id pub-id-type="pmid">10416590</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggert</surname><given-names>AA</given-names></name><name><surname>van der Voort</surname><given-names>R</given-names></name><name><surname>Torensma</surname><given-names>R</given-names></name><name><surname>Moulin</surname><given-names>V</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><etal/></person-group><article-title>Analysis of dendritic cell trafficking using EGFP-transgenic mice</article-title><source>Immunol Lett</source><year>2003</year><volume>89</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(03)00105-6</pub-id><pub-id pub-id-type="pmid">12946860</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Akabani</surname><given-names>G</given-names></name><name><surname>Niehaus</surname><given-names>N</given-names></name><name><surname>Coleman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Migration of human dendritic cells after injection in patients with metastatic malignancies</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>56</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9892184</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>IJ</given-names></name><name><surname>Krooshoop</surname><given-names>DJ</given-names></name><name><surname>Scharenborg</surname><given-names>NM</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Diepstra</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">12517769</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macatonia</surname><given-names>SE</given-names></name><name><surname>Knight</surname><given-names>SC</given-names></name><name><surname>Edwards</surname><given-names>AJ</given-names></name><name><surname>Griffiths</surname><given-names>S</given-names></name><name><surname>Fryer</surname><given-names>P</given-names></name></person-group><article-title>Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies</article-title><source>J Exp Med</source><year>1987</year><volume>166</volume><fpage>1654</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1084/jem.166.6.1654</pub-id><pub-id pub-id-type="pmid">3119761</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruedl</surname><given-names>C</given-names></name><name><surname>Koebel</surname><given-names>P</given-names></name><name><surname>Bachmann</surname><given-names>M</given-names></name><name><surname>Hess</surname><given-names>M</given-names></name><name><surname>Karjalainen</surname><given-names>K</given-names></name></person-group><article-title>Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>4910</fpage><lpage>4916</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.9.4910</pub-id><pub-id pub-id-type="pmid">11046016</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Oran</surname><given-names>A</given-names></name><name><surname>Wajchman</surname><given-names>J</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Maris</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1038/ni962</pub-id><pub-id pub-id-type="pmid">12910266</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdijk</surname><given-names>P</given-names></name><name><surname>Aarntzen</surname><given-names>EH</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Boullart</surname><given-names>AC</given-names></name><name><surname>Kok</surname><given-names>E</given-names></name><etal/></person-group><article-title>Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>2531</fpage><lpage>2540</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2729</pub-id><pub-id pub-id-type="pmid">19318472</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Lambeck</surname><given-names>AJ</given-names></name><name><surname>Aarntzen</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>5725</fpage><lpage>5735</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1261</pub-id><pub-id pub-id-type="pmid">21771874</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringel</surname><given-names>F</given-names></name><name><surname>Pape</surname><given-names>H</given-names></name><name><surname>Sabel</surname><given-names>M</given-names></name><name><surname>Krex</surname><given-names>D</given-names></name><name><surname>Bock</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection</article-title><source>Neuro-Oncology</source><year>2016</year><volume>18</volume><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nov145</pub-id><pub-id pub-id-type="pmid">26243790</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suchorska</surname><given-names>B</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Tabatabai</surname><given-names>G</given-names></name><name><surname>Senft</surname><given-names>C</given-names></name><name><surname>Hau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial</article-title><source>Neuro-Oncology</source><year>2016</year><volume>18</volume><fpage>549</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nov326</pub-id><pub-id pub-id-type="pmid">26823503</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Kohanbash</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Hoji</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunotherapeutic approaches for glioma</article-title><source>Crit Rev Immunol</source><year>2009</year><volume>29</volume><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v29.i1.10</pub-id><pub-id pub-id-type="pmid">19348609</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grauer</surname><given-names>OM</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name></person-group><article-title>Immunotherapy of diffuse gliomas: biological background, current status and future developments</article-title><source>Brain Pathol</source><year>2009</year><volume>19</volume><fpage>674</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2009.00315.x</pub-id><pub-id pub-id-type="pmid">19744040</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubinski</surname><given-names>D</given-names></name><name><surname>Wolfer</surname><given-names>J</given-names></name><name><surname>Hasselblatt</surname><given-names>M</given-names></name><name><surname>Schneider-Hohendorf</surname><given-names>T</given-names></name><name><surname>Bogdahn</surname><given-names>U</given-names></name><etal/></person-group><article-title>CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients</article-title><source>Neuro-Oncology</source><year>2015</year><volume>18</volume><fpage>807</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nov280</pub-id><pub-id pub-id-type="pmid">26578623</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Safaee</surname><given-names>M</given-names></name><name><surname>Lisiero</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e32614</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0032614</pub-id><pub-id pub-id-type="pmid">22485134</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JF</given-names></name><name><surname>Idema</surname><given-names>AJ</given-names></name><name><surname>Bol</surname><given-names>KF</given-names></name><name><surname>Nierkens</surname><given-names>S</given-names></name><name><surname>Grauer</surname><given-names>OM</given-names></name><etal/></person-group><article-title>Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors</article-title><source>Neuro-Oncology</source><year>2009</year><volume>11</volume><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1215/15228517-2008-104</pub-id><pub-id pub-id-type="pmid">19028999</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>De Rosa</surname><given-names>SC</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation</article-title><source>J Immunol Methods</source><year>2003</year><volume>281</volume><fpage>65</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(03)00265-5</pub-id><pub-id pub-id-type="pmid">14580882</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutoit</surname><given-names>V</given-names></name><name><surname>Herold-Mende</surname><given-names>C</given-names></name><name><surname>Hilf</surname><given-names>N</given-names></name><name><surname>Schoor</surname><given-names>O</given-names></name><name><surname>Beckhove</surname><given-names>P</given-names></name><etal/></person-group><article-title>Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy</article-title><source>Brain</source><year>2012</year><volume>135</volume><fpage>1042</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1093/brain/aws042</pub-id><pub-id pub-id-type="pmid">22418738</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>IF</given-names></name><name><surname>Jakacki</surname><given-names>RI</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Panigrahy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas</article-title><source>Neuro-Oncology</source><year>2016</year><volume>18</volume><fpage>1157</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now026</pub-id><pub-id pub-id-type="pmid">26984745</pub-id></element-citation></ref></ref-list></back></article>